rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ABBV
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Abbvie stock price target raised to $349 by Piper Sandler on growth
      13h agoInvesting.comABBVPIPR
      Barclays Reaffirms Their Buy Rating on AbbVie (ABBV)

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Nov 17The Globe and MailABBV
      These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Nov 17The Globe and MailABBVBDX
      AbbVie (ABBV) Expands Its Pipeline With New AI Drug Discovery Partnerships
      Nov 16Yahoo FinanceABBV
      AbbVie (ABBV) Stock Looks Below Fair Value After Strong Cash Flow Growth
      Nov 14Yahoo FinanceABBV
      3 Dividend Stocks Built for a Market Priced Like It's 1999

      Detailed price information for JP Morgan Chase & Company (JPM-N) from The Globe and Mail including charting and trades.

      Nov 13The Globe and MailABBV
      How Did AbbVie's Immunology Franchise Fare in Q3?
      Nov 12Yahoo FinanceABBV
      AbbVie Deal Altering The Investment Case For Nxera Pharma Stock (TSE:4565)?
      Nov 12Yahoo FinanceABBV
      The Zacks Analyst Blog Highlights NVIDIA, Walmart, AbbVie, Pioneer Bancorp and Aspira

      NVDA, WMT and ABBV headline Zacks' latest research, with growth drivers and business risks shaping their investment outlooks.

      Nov 12Yahoo FinanceTBBKABBVWMT
      AbbVie (ABBV) Reports Positive Phase 3 QULIPTA Migraine Trial Results
      Nov 12Yahoo FinanceABBV
      ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Nov 12The Globe and MailABBV
      Top Analyst Reports for NVIDIA, Walmart & AbbVie
      Nov 11Yahoo FinanceABBVWMT
      ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Nov 11The Globe and MailABBV
      Can AbbVie (ABBV) Justify Its Valuation After Raised Guidance And Strong Results?
      Nov 10Yahoo FinanceABBV
      Told she shouldn’t pursue a dance career, she made a life-changing choice

      When Crohn’s disease forced Sunny Dee to put her dance career on hold, she built a community through podcasting. Learn how she’s staying optimistic in the face of chronic illness. (Partner Content)

      Nov 10The Washington PostABBV
      While pharma peers stumble, AbbVie defeated the patent cliff
      Nov 10Yahoo FinanceABBV
      Zacks Investment Ideas feature highlights: Moderna, AbbVie, Eli Lilly and Merck
      Nov 9Yahoo FinanceMRNAABBVLLYMRK
      AbbVie reports improved facial satisfaction among weight-loss drug users (ABBV:NYSE)

      AbbVie sees potential Botox and filler demand from GLP-1 users as small studies show improved facial satisfaction after cosmetic treatments.

      Nov 9Seeking AlphaABBV
      Why Is AbbVie (ABBV) Spending $1.37 Billion On Pipeline And UK Research?
      Nov 7Yahoo FinanceABBV
      Pfizer vs. AbbVie: Higher Yield and Cheaper Valuation Give One the Clear Edge
      Nov 7BarchartABBVPFE
      AbbVie Inc. stock underperforms Friday when compared to competitors despite daily gains
      Nov 6MarketWatchABBV
      Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today
      Nov 6BenzingaABBV
      The One Thing To Settle Before Buying AbbVie Stock
      Nov 6Yahoo FinanceABBV
      3 Dividend Kings to Buy in November and Never Sell | The Motley Fool

      These are arguably among the most reliable dividend payers.

      Nov 5The Motley FoolABBV
      AbbVie stock hits all-time high at 298.74 USD
      Nov 5Investing.comABBV
      Are Wall Street Analysts Bullish on AbbVie Stock?
      Nov 5BarchartABBV
      AbbVie (ABBV) Stock Climbs As Q3 Earnings Fuel Growth Case
      Nov 5Yahoo FinanceABBV
      Abbvie's Nxera deal, Nooks $500m, and the birth of Onvaro
      Nov 4AxiosABBV
      AbbVie Inc. stock underperforms Wednesday when compared to competitors despite daily gains
      Nov 4MarketWatchABBV
      AbbVie, Nxera ink licensing deal worth up to $1.5B (ABBV:NYSE)

      AbbVie (ABBV) agrees to buy exclusive global rights to develop and commercialize a bowel disease drug from Nxera Pharma in a deal worth up to $1.5B. Read more here.

      Nov 4Seeking AlphaABBV
      AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
      Nov 4Investing.comABBV
      AbbVie bolsters UK R&D presence, inks $1.38bn IBD deal with Nxera
      Nov 4Yahoo FinanceABBV
      Analysts Are Bullish on These Healthcare Stocks: Aurinia Pharmaceuticals (AUPH), AbbVie (ABBV)

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Nov 4The Globe and MailAUPHABBV
      Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease

      Nxera to receive US$100 million upfront and be eligible for up to US$1.37 billion in development and commercial milestone payments, plus tiered royalties.NXE0033744, an investigational oral EP4 receptor agonist discovered using Nxera’s NxWave™ drug discovery platform, is a potential first-in-class candidate for inflammatory bowel disease. Tokyo, Japan and Cambridge, UK, 4 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”; TSE: 4565) today announces that its subsidiary, Nxera Pharm

      Nov 4Yahoo FinanceABBV
      AbbVie expands Oxford R&D facility as part of £120 million-plus investment By Reuters
      Nov 4Investing.comABBV
      AbbVie expands Oxford R&D facility as part of £120 million-plus investment
      Nov 4ReutersABBV
      AbbVie (ABBV) Receives a Rating Update from a Top Analyst

      Tipranks Press Release.

      Nov 3The Globe and MailABBV
      AbbVie Hit a New High After Earnings. There’s More Upside Left.
      Nov 3Yahoo FinanceABBV
      AbbVie inks $757m migraine-focused deal with Brise Pharmaceuticals
      Nov 3Yahoo FinanceABBV
      ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Nov 3The Globe and MailABBV
      AbbVie Earnings Call Signals Strong Growth Ahead

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Nov 3The Globe and MailABBV
      AbbVie Stocks Decline 2.3% With RBC Target Increase Backing Its Immunology Transition
      Nov 2Yahoo FinanceABBV
      ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Nov 2The Globe and MailABBV
      AbbVie Analysts Raise Price Target After Q3 Print, Expect Growth To Reaccelerate
      Nov 2BenzingaABBV
      AbbVie License Deal With Brise Potentially Valued at $757 Million
      Nov 2Yahoo FinanceABBV
      AbbVie (ABBV) Lands Phase 3 Migraine Study Win In The Lancet Neurology
      Nov 2Yahoo FinanceABBV
      AbbVie Earnings: Raising Our Fair Value Estimate With Significant Pipeline Progress

      AbbVie stock still trades at a premium to our new valuation.

      Nov 2MorningstarABBV
      Cantor Fitzgerald raises Abbvie stock price target on immunology pipeline
      Nov 2Investing.comABBV
      Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
      Nov 2Yahoo FinanceABBV
      Bernstein raises Abbvie stock price target to $275 on pipeline strength
      Nov 2Investing.comABBV

      This is the newest page. Registered accounts read further back.